<?xml version="1.0" encoding="UTF-8"?>
<author-notes>
 <corresp id="cor1">Address correspondence to Hossein Khalili, 
  <email>Khalilih@sina.tums.ac.ir</email>.
 </corresp>
 <fn fn-type="other">
  <p>
   <bold>Citation</bold> Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, Kazemzadeh H, Yekaninejad MS. 2020. A randomized clinical trial of the efficacy and safety of interferon Î²-1a in treatment of severe COVID-19. Antimicrob Agents Chemother 64:e01061-20. 
   <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.01061-20" xmlns:xlink="http://www.w3.org/1999/xlink">https://doi.org/10.1128/AAC.01061-20</ext-link>.
  </p>
 </fn>
</author-notes>
